Which Antihypertensive Drug Matters. Part 2

In another legal proceeding, Patricia McGettigan, MB BS, PhD, and
David William Henry, MB ChB, from the Body of Newcastle, New South
Wales, Australia, conducted a meta-analysis of the observational
studies in the medical written material to compare the risks of serious
cardiovascular events (predominantly MI) with mortal arcoxia and COX-2
inhibitors. Support for this recapitulation was provided through plan
grants from the National Eudaimonia and Medical Investigating
Administrative unit of Australia and the National Center Founding
State.
The literary criticism was based on 17 case-control analyses that
included 86,193 cases with cardiovascular events and over 500,000
controls using selective COX-2 inhibitors or NSAIDs (mainly ibuprofen,
diclofenac, naproxen, indomethacin, or piroxicam) and 6 company
analyses that included 75,520 users of selective COX-2 inhibitors,
375,619 users of nonselective NSAIDs, and 594,720 unexposed
participants.

A dose-related risk was found with rofecoxib (relative risk 1.33
with ≤ 25 mg/day and 2.19 with > 25 mg/day), the authors write up.
The risk was elevated during the starting time 30 days of direction.
Celecoxib was not associated with increased risk of vascular attack.
Diclofenac, indomethacin, and probably meloxicam were also associated
with increased risk.
The authors conclude that their psychotherapy confirms a dose-related
risk of cardiovascular events with selective COX-2 inhibitors and that,
based on the observational studies, the risk increases early in care.
They add that diclofenac, an older NSAID, also appears to effort this
risk and that “there are information for reviewing its regulatory
state.”

This is a part of article Which Antihypertensive Drug Matters. Part 2 Taken from "Generic Arcoxia (Etoricoxib)" Information Blog